.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The SAXOPHONE trial recently highlighted the safety of using apixaban in pediatric heart disease for thromboprophylaxis. Within this primary trial design, researchers included an exploratory substudy to evaluate the drug's impact on surrogate biomarkers of efficacy. Specifically, the medical team monitored changes in d-dimer levels, thrombin generation assay (TGA) parameters, and various hemostatic proteins. By comparing apixaban to standard-of-care treatments like vitamin K antagonists (VKAs) and low-molecular-weight heparin, the study provides valuable insights into pediatric anticoagulation management.
The results showed that d-dimer levels decreased significantly at the six-month mark across all treatment groups. Furthermore, the findings indicated that apixaban in pediatric heart disease significantly prolonged the TGA lag time and the time to peak compared to VKAs. This suggests a potent reduction in hypercoagulability. Although apixaban reduced peak thrombin similarly to VKAs in anticoagulant-naïve patients, it effectively preserved the endogenous thrombin potential. Consequently, these changes align with observations previously recorded in adult populations, supporting the clinical efficacy of this direct oral anticoagulant.
Regarding hemostatic proteins, apixaban decreased fibrinogen and factor VIII levels at six months. However, the drug did not significantly alter protein C or protein S levels. Additionally, prior exposure to VKAs caused noticeable carryover effects, which suppressed baseline d-dimer and other protein levels. Overall, the substudy supports the primary outcomes of the SAXOPHONE trial. It reinforces the favorable risk-benefit profile of apixaban as a convenient and effective option for children requiring long-term anticoagulation. These findings offer clinicians a more predictable alternative to traditional therapies that often require frequent monitoring.
It demonstrates that apixaban successfully reduces markers of hypercoagulability, such as d-dimer, and prolongs thrombin generation lag time in children with heart disease.
According to the trial data, apixaban does not have a significant effect on protein C or protein S levels in pediatric patients with heart disease.
The study indicates that apixaban provides similar reductions in hypercoagulability and peak thrombin as vitamin K antagonists, while offering a more favorable safety and convenience profile.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional recommendation. Always seek the advice of a qualified healthcare provider regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A substudy of the SAXOPHONE trial reveals how apixaban affects hemostatic biomarkers and thrombin generation in children with heart disease....
7 months ago
Following Nigeria's first recorded Ebola case linked to regional travel, the Africa CDC has convened an emergency ministerial summit. This alert underscores critical clinical priorities for healthcare professionals, including differentiating early viral infection from malaria, implementing barrier nursing, and triage.
Today
Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today
